Adare

The Evolution of the CDMO Industry

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.

News

Adare to Expand Oral Dose Capabilities in Italy

US CDMO Adare Pharma Solutions is to add a high-shear mixer granulator at its Pessano, Italy facility, to complement existing fluid bed capabilities. The new mixer can provide wet granulation using either aqueous or organic-based solutions.

News

DSM in Talks to Take Adare Biome

DSM is in exclusive talks with US CDMO Adare Pharma Solutions to buy Adare Biome, a French developer and manufacture of postbiotics, for €275 million.

Top-Feature

INOSIM GmbH

Predictive Simulation in Pharma Production

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Evonik Industries AG

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.